A PHP Error was encountered

Severity: Warning

Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests

Filename: helpers/my_audit_helper.php

Line Number: 176

Backtrace:

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 1034
Function: getPubMedXML

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3152
Function: GetPubMedArticleOutput_2016

File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global

File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword

File: /var/www/html/index.php
Line: 316
Function: require_once

Updated Results of Rituximab Pre- and Post-BEAM with or without Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma. | LitMetric

We evaluated the effect on long-term survival of adding rituximab (R) to BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning with or without yttrium-90 ibritumomab tiuxetan (YIT) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) undergoing autologous stem cell transplant (ASCT). Patients were enrolled on three consecutive phase II clinical trials. Patients received two doses of rituximab (375 and 1,000 mg/m) during mobilization of stem cells, followed by 1,000 mg/m on days +1 and +8 after ASCT with R-BEAM or YIT-R-BEAM (YIT dose of 0.4 mCi/kg) conditioning. One hundred thirteen patients were enrolled, with 73 receiving R-BEAM and 40 receiving YIT-R-BEAM. All patients had a prior exposure to rituximab. The median follow-up intervals for survivors were 11.8, 8.1, and 4.2 years in the three trials, respectively. The 5-year disease-free survival (DFS) rates were 62% for R-BEAM and 65% for YIT-R-BEAM ( = 0.82). The 5-year overall survival rates were 73% and 77%, respectively ( = 0.65). In patients with DLBCL, survival outcomes of the germinal center/activated b-cell histologic subtypes were similar with 5-year OS rates ( = 0.52) and DFS rates ( = 0.64), irrespective of their time of relapse (<1 vs. >1 year) after initial induction chemotherapy ( = 0.97). Administering ASCT with rituximab during stem cell collection and immediately after transplantation induces long-term disease remission and abolishes the negative prognostic impact of cell-of-origin in patients with relapsed DLBCL. The addition of YIT does not confer a further survival benefit. .

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955837PMC
http://dx.doi.org/10.1158/1078-0432.CCR-17-3561DOI Listing

Publication Analysis

Top Keywords

ibritumomab tiuxetan
8
diffuse large
8
large b-cell
8
b-cell lymphoma
8
patients relapsed
8
stem cell
8
patients enrolled
8
1000 mg/m
8
dfs rates
8
patients
7

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!